Financials Results for half year ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Clinitech Laboratory Limited announced its unaudited financial results for the half year ended September 30, 2025. Revenue from operations stood at Rs 415.89 lakhs, down from Rs 508.02 lakhs in the same period last year. Total expenses rose sharply to Rs 483.93 lakhs from Rs 387.03 lakhs, leading to a profit before tax of Rs 29.52 lakhs (vs Rs 35.09 lakhs). However, profit after tax improved to Rs 37.12 lakhs (vs Rs 17.37 lakhs) helped by deferred tax adjustments, with basic EPS at Rs 1.32 versus Rs 0.17 earlier. Operating cash flow remained negative at Rs -87.87 lakhs, and cash balance fell to Rs 245.90 lakhs. The Board also approved the formation of a new subsidiary, and auditors gave a clean limited review report. Of the Rs 578.30 lakhs raised via IPO, Rs 428.30 lakhs has been utilized, with Rs 150 lakhs (for diagnostic business expansion) still pending deployment.
Mixed signals for shareholders — top-line decline and higher expenses are concerns, but PAT more than doubled on tax benefits. The pending IPO fund deployment and subsidiary formation could shape future growth, though near-term cash burn needs watching.